<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952129</url>
  </required_header>
  <id_info>
    <org_study_id>OSCAR</org_study_id>
    <nct_id>NCT04952129</nct_id>
  </id_info>
  <brief_title>Optimal Selenium for Bowel Polyps (OSCAR)</brief_title>
  <acronym>OSCAR</acronym>
  <official_title>Randomised Phase Ib Trial to Determine the Optimal Selenium Status to Prevent Colorectal Adenoma Recurrence: OSCAR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Trials New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Counties Manukau Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Waikato Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Auckland, New Zealand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      New Zealand (NZ) has high bowel cancer rates, which the Bowel Screening Programme aims to&#xD;
      reduce by early detection of bowel cancer and its precursor, adenomas (polyps). Bowel cancer&#xD;
      and adenoma rates are higher in countries like NZ with low intake of the essential trace&#xD;
      mineral selenium. Overseas, trials of selenium supplements reduced adenoma recurrence in&#xD;
      people with low blood selenium, but not with high levels (where adding selenium increased&#xD;
      health risks). Laboratory research explained this, and found certain types of selenium are&#xD;
      safer and more effective. The optimal type and dose of selenium to use in NZ cancer&#xD;
      prevention trials is not known.&#xD;
&#xD;
      The main objective of this trial is to evaluate which dose and type of selenium (either&#xD;
      selenomethionine or methylselenocysteine) gives optimal selenium status to maximise cancer&#xD;
      prevention without causing health problems from excessive selenium intake. We also want to&#xD;
      see how much selenium is needed according to selenium blood levels before starting selenium&#xD;
      in the trial. Side effects will be evaluated, as will recruitment rates.&#xD;
&#xD;
      This will determine the feasibility of developing a large randomised trial of selenium to&#xD;
      reduce the recurrence rates for advanced adenomas in NZ.&#xD;
&#xD;
      This trial will recruit 60 patients from Middlemore and Waikato Hospitals with an advanced&#xD;
      adenoma removed through the Bowel Screening Programme. Patients will take one selenium&#xD;
      compound, dosed at 50 mcg/day for 6 weeks then 100 mcg/day for 6 weeks, and will have blood&#xD;
      tests at baseline, then blood tests and evaluation of side effects at 6 weeks and 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma SEPP1 concentration 1</measure>
    <time_frame>At 6 weeks</time_frame>
    <description>To determine whether 50 micrograms/day of selenium for 6 weeks significantly increases plasma SEPP1 from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma SEPP1 concentration 2</measure>
    <time_frame>At 6 and 12 weeks</time_frame>
    <description>To determine whether the change in plasma SEPP1 from baseline is greater with selenium 100 micrograms/day than 50 micrograms/day only when baseline plasma selenium is below the median value for the trial population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma SEPP1 concentration 3</measure>
    <time_frame>At 6 and 12 weeks</time_frame>
    <description>To determine whether the change in plasma SEPP1 from baseline is not different between methylselenocysteine and selenomethionine at each dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma selenium</measure>
    <time_frame>At 6 and 12 weeks</time_frame>
    <description>To determine change in plasma selenium levels by selenium type and dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse effects</measure>
    <time_frame>At all time points</time_frame>
    <description>To determine the incidence of treatment-emergent adverse effects as classified according to NCI-CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell DNA damage</measure>
    <time_frame>At 6 and 12 weeks</time_frame>
    <description>To determine change in DNA damage (relative to baseline) by selenium type and dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recruitment</measure>
    <time_frame>At baseline</time_frame>
    <description>To determine to percentage of subjects who after being offered the study continue on to study entry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Adenoma</condition>
  <arm_group>
    <arm_group_label>Selenomethionine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 micrograms of selenium as Selenomethionine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylselenocysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 micrograms of selenium as Methylselenocysteine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenomethionine</intervention_name>
    <description>Seleno-amino acid</description>
    <arm_group_label>Selenomethionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylselenocysteine</intervention_name>
    <description>Seleno-amino acid</description>
    <arm_group_label>Methylselenocysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants will have all of the following:&#xD;
&#xD;
          -  pathologically-confirmed advanced adenoma (defined as any one of &gt;/= 10mm diameter,&#xD;
             &gt;/= 3 adenomas, high-grade dysplasia, tubulovillous or villous adenoma) 5 diagnosed at&#xD;
             first colonoscopy in the National bowel screening programme within the previous 6&#xD;
             months;&#xD;
&#xD;
          -  no residual colorectal adenomas;&#xD;
&#xD;
          -  next colonoscopy planned within 5 years;&#xD;
&#xD;
          -  willing and able to comply with all trial requirements, including treatment and&#xD;
             assessments;&#xD;
&#xD;
          -  signed written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants will have none of the following:&#xD;
&#xD;
          -  currently taking selenium supplements (including in multivitamins) or within the last&#xD;
             6 weeks;&#xD;
&#xD;
          -  previous history of colorectal adenoma, colorectal cancer or familial colorectal&#xD;
             cancer syndrome;&#xD;
&#xD;
          -  other significant cancers within the last 5 years;&#xD;
&#xD;
          -  concurrent medical conditions that, in the opinion of the investigators, would&#xD;
             compromise either participant safety or the integrity of the data (e.g.,&#xD;
             malabsorption);&#xD;
&#xD;
          -  male participants with a female partner of childbearing potential or pregnant, and&#xD;
             unwilling to remain abstinent or use effective contraception (including barrier&#xD;
             contraception with a pregnant partner).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Jameson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Auckland, New Zealand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Jameson, PhD</last_name>
    <phone>+64 7 8398750</phone>
    <email>michael.jameson@waikatodhb.health.nz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Waikato DHB</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Jameson, PhD</last_name>
      <phone>+64 7 8398750</phone>
      <email>michael.jameson@waikatodhb.health.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Counties Manukau DHB</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <contact>
      <last_name>Maree Weston, MBChB</last_name>
      <phone>+64 9 276 0000</phone>
      <email>Maree.Weston@middlemore.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Auckland, New Zealand</investigator_affiliation>
    <investigator_full_name>Michael Jameson</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>selenium</keyword>
  <keyword>colorectal adenoma</keyword>
  <keyword>selenomethionine</keyword>
  <keyword>methylselenocysteine</keyword>
  <keyword>selenoprotein P</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Selenomethylselenocysteine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

